News
Displaying 151–160 of 541
-
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Research NewsReports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
Research NewsThe company is planning to move the emerging treatment into a pivotal trial
-
Research News
Small data sets present challenges for developing rare disease AI tools
-
Foundation News
Initiatives to increase engagement and awareness around blinding retinal diseases.
-
RD Fund Participates in a €75 Million Series B for SparingVision
In the PressProceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
-
Foundation Fighting Blindness Makes Key Appointments to Leadership Team
Foundation NewsSeveral executives promoted to continue the advancement of the Foundation’s notable research and philanthropic efforts.
-
Iveric Bio’s Zimura for Advanced Dry AMD Meets Endpoint in Second Phase 3 Clinical Trial
Research NewsThe company plans to seek FDA approval for the emerging therapy in first quarter of 2023
-
Belite Bio Launching Phase 3 Clinical Trial for Stargardt Disease Drug
Research NewsThe company’s drug is designed to reduce accumulation of toxins that cause vision loss.
-
ProQR Seeking to Partner Ophthalmic Programs
Research NewsThe company is halting its clinical programs for LCA10 and USH2A as it seeks a new partner
-
Research News
Funding for the new grants was made possible by Foundation’s strong donor base and philanthropic partners
.png)
